Hyderabad: Dr Reddy`s Laboratories Limited, (DRL) a global pharmaceutical giants, registered a growth of 120 per cent in the profit after tax for the first quarter of the financial year 2009-10 while the overall revenue was at Rs 1,818.9 crores against Rs 1,503.8 crores of the previous year, registering a growth of 21 per cent.
Announcing the unaudited financial results for the
first quarter ended June 30, under international financial
reporting standards (IFRS), G V Prasad, Vice Chairman and
Chief Executive Officer told reporters here today.
That profit after tax (PAT) for the first quarter was
registered at Rs 244.5 crores against Rs 110 crores in the
previous Q1 of 2008-09 which was up by 120 per cent.
He said that the growth was largedly driven by
Sumpatriptan and the revenues from global generics business
was at Rs 1300 crores in Q1 FY 2010 as against Rs 1030 crores
in Q1 of FY 2008-09.
Year on Year growth of 27 per cent was driven by
Sumpatriptan and key markets of north Amercia and India.
Excluding revenue from Sumatriptan the year on year growth
is at 7 per cent. Sumpatriptan continues to hold 50 per cent
market in north Amercia.